
|Articles|June 22, 2022
Pointers With Portela: New FDA Treatment for Alopecia Areata
Author(s)Dustin Portela, DO
In this week’s Pointers with Dr Portela, the 208SkinDoc talks the newest approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata.
Advertisement
Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks the FDA approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata. He talked about the data and explained the adverse events seen with this treatment.
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
2
Translational Takeaways: June 7, 2026
3
The Emerging Role of Oral Peptide Therapeutics in Dermatology
4
Dermatology Times Spot Test: June 7, 2026
5














